EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers

21 Sep by Vitaliy Dadalyan

EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers

Share the love y'all!

EU agency recommends AstraZeneca-Merck drug Lynparza for two cancersProstate cancer is the second-most common type of cancer in men worldwide, while ovarian cancer is the fifth most common cause of cancer death in Europe. The EMA recommendation follows positive regulatory updates for Lynparza, which AstraZeneca has developed with Merck & Co Inc as it faces competition from British rival GlaxoSmithKline on cancer drugs.